<DOC>
	<DOCNO>NCT02635750</DOCNO>
	<brief_summary>Part I : To investigate whether extent donepezil affect single dose pharmacokinetics BI 409306 Part II : To investigate whether extent BI 409306 affect single dose pharmacokinetics donepezil</brief_summary>
	<brief_title>Investigation Pharmacokinetic Drug-drug Interaction BI 409306 Donepezil Healthy Male Female Subjects</brief_title>
	<detailed_description />
	<mesh_term>Donepezil</mesh_term>
	<criteria>Inclusion criterion : Healthy male/female subject , age 18 55 year , body mass index ( BMI ) 18.5 29.9 kg/m2 Signed date write informed consent prior admission study accordance GCP local legislation Male subject , female subject meet follow criterion start least 30 day first administration trial medication 30 day trial completion : Use adequate contraception , e.g . follow method plus condom : intrauterine device ( nonhormonal ) Sexually abstinent A vasectomised sexual partner ( vasectomy least 1 year prior enrolment ) Surgically sterilise ( include hysterectomy ) Postmenopausal , define least 1 year spontaneous amenorrhea ( questionable case blood sample simultaneous level FSH 40 U/L estradiol 30 ng/L confirmatory ) Exclusion criterion : Any find medical examination ( include BP , PR ECG ) deviate normal judge clinically relevant investigator Repeated measurement systolic blood pressure outside range 90 140 mmHg , diastolic blood pressure outside range 50 90 mmHg , pulse rate outside range 60 90 bpm Any laboratory value outside reference range investigator considers clinical relevance Any evidence concomitant disease judge clinically relevant investigator Gastrointestinal , hepatic , renal , respiratory , cardiovascular , metabolic , immunological hormonal disorder Surgery gastrointestinal tract could interfere kinetics trial medication ( except appendectomy simple hernia repair ) Diseases central nervous system ( include limit kind seizure stroke ) , relevant neurological psychiatric disorder History relevant orthostatic hypotension , faint spell , blackout Chronic relevant acute infection History relevant allergy hypersensitivity ( include allergy trial medication excipients ) Intake drug long halflife ( 24 h ) within 30 day less 10 halflives respective drug prior administration trial medication Within 10 day prior administration trial medication , use drug might reasonably influence result trial might prolong QT/QTc interval Participation another trial investigational drug administer within 60 day prior plan administration trial medication Smoker Alcohol abuse Further exclusion criterion apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>